跳至主要内容
临床试验/NCT04592185
NCT04592185进行中(未招募)不适用

Post-registration Observational Study on the Custom-made Abdominal Aortic Endograft Fenestrated Anaconda™

Vascutek Ltd.33 个研究点 分布在 1 个国家目标入组 106 人开始时间: 2019年10月21日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
106
试验地点
33
主要终点
Long-term outcome of use of Fenestrated Anaconda

研究概览

简要总结

The French Ministry registered the Fenestrated Anaconda ™ on the List of Reimbursable Products and Services (LPPR) by the French Health Insurance on February 2018 for a duration of 5 years, while taking up the conditions for carrying out the act recommended by the CNEDiMTS (Committee in charge of medical device review), namely the carrying out of a post-registration study for the renewal of the authorization. This renewal of registration is conditioned by the set-up of a long-term follow-up study of all patients treated with the Fenestrated Anaconda ™ in France.

To do this, this study will be carried out in partnership with the Federation of Medical Specialties (FSM) and the National Professional Council (CNP) of Vascular Surgery in order to have the data necessary for the renewal of the registration of the Fenestrated Anaconda ™ from the registry called Datavasc developed by the CNP and available online on the FSM's electronic platform.

详细描述

EPI-EFA study: Post-registration study of the Fenestrated Anaconda™ in the management of a complex abdominal, juxtarenal, pararenal, suprarenal aortic aneurysm, whether or not associated with a distal common iliac artery or thoracoabdominal aneurysm type IV, in high-risk patients requiring treatment, for whom a surgical contraindication has been asked.

  • Study type : observational, national, multi-centre, prospective, non-comparative study, as open registry
  • Primary objective : To evaluate the long-term interest of Fenestrated Anaconda™ on all patients treated with in France. The data collected should be:
  • 1-year mortality rate related to device, procedure, any cause = primary endpoint
  • Stent-related adverse events (endoleak, migration, integrity of the device), renal events, ischemia (medullary (paraplegia / paraparesis), intestinal) = secondary endpoints
  • Study timelines :
  • Duration / follow-up :
  • 1-year recruitment period from October 2019, with a minimum of 91 patients
  • Mid-term follow-up : at 1 year
  • Routine practice : until 5 years
  • Reports to be submitted to French Health Authority :
  • Interim report with mid-term follow-up data for renewal dossier
  • Final report with long-term follow-up data

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Long-term outcome of use of Fenestrated Anaconda

时间窗: 1 year

Device-related mortality, procedure-related mortality, all-cause mortality

次要结局

  • Stent-related adverse events(5 years)
  • Renal adverse events(5 years)
  • Ischemia(5 years)

研究者

发起方
Vascutek Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (33)

Loading locations...

相似试验